Jump to content

Milameline

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Addbot (talk | contribs) at 21:44, 20 March 2013 (Bot: Migrating 1 interwiki links, now provided by Wikidata on d:q6850472). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Milameline
Clinical data
ATC code
  • None
Identifiers
  • (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.220.595 Edit this at Wikidata
Chemical and physical data
FormulaC8H14N2O
Molar mass154.21 g/mol g·mol−1
3D model (JSmol)
  • N(/OC)=C\C1=C\CCN(C)C1

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]

See also

References

  1. ^ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–82. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.{{cite journal}}: CS1 maint: multiple names: authors list (link)


Template:Nootropics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Milameline&oldid=545791048"